Publications by authors named "Andromachi Reklou"
Article Synopsis
- * A study with 75 individuals highlighted that the duration of diabetes affected presepsin levels, with type 1 diabetes patients showing higher levels compared to type 2 diabetes patients, especially in well-controlled groups.
- * After considering other factors like age and body mass index, the difference in presepsin levels remained significant, indicating its possible role as a marker for inflammation in diabetes management.
Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated.
View Article and Find Full Text PDFArticle Synopsis
- Statin treatment is beneficial for both non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) in NAFLD patients.
- The review focuses on the role of PCSK9 in NAFLD development and the impact of new drugs that inhibit PCSK9.
- Research shows that lowering PCSK9 levels with specific inhibitors can protect the liver from NAFLD while also offering CVD benefits, regardless of their effects on LDL cholesterol levels.
Background: The treatment of type 2 diabetes mellitus (T2DM) is complex; only a few patients successfully attain glycemic targets with monotherapy, most requiring drug combination therapy.
Methods: The goal of this review was to identify in PubMed the complimentary ways of action leading to clinical benefit (in lowering HbA1c, body weight, renal, and cardiac risk factors and events) of the combination of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Results: SGLT2i, an emerging class of antidiabetic agents with an insulin-independent mechanism of action, are suitable for use in combination with any other class of antidiabetics, including insulin.
Background: Low density lipoprotein cholesterol (LDL-C) and low grade arterial inflammation are key pathogenic factors for atherosclerosis and its manifestation, cardiovascular disease (CVD).
Objective: In this narrative review we assessed if decreasing LDL-C levels or inflammation or both is more effective in reducing CVD events.
Results: In the Scandinavian Simvastatin Survival Study (4S), all statin trials of the 90s' and the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) the benefit came from the LDL-C reduction.
Purpose. Pheochromocytoma in association with pregnancy is a very rare, without specific symptoms, life-threatening condition, increasing both maternal and fetal mortality up to 50%. The present paper illustrates the case of a pregnant woman, diagnosed with pheochromocytoma, aiming to demonstrate and discuss the difficulties that arouse during the diagnosis and the problems concerning the treatment.
View Article and Find Full Text PDF